Solid Biosciences

Today, Solid announced positive initial clinical data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy candidate intended for the treatment of #Duchenne muscular dystrophy. Read the full release: investors.solidbio.com/news-releases/… $SLDB

Solid Biosciences today announced our financial results for the fourth quarter and full year 2025, along with business and pipeline updates. Read the full release: investors.solidbio.com/news-releases/… #SolidBiosciences $SLDB

Solid in the news! This is a very exciting time for our team at Solid Biosciences and the Friedreich’s ataxia (FA) community. Recently, our Chief Medical Officer, Gabriel Brooks, M.D. and Russell R. Lonser, M.D. from The Ohio State University Wexner Medical Center, sat down with @CheckRare podcast to discuss our Phase 1b FALCON clinical trial and the milestone of dosing the first participant with SGT-212, our investigational gene therapy for the treatment of FA. FA is a rare, inherited disease with a devastating impact on neuromuscular and cardiac function. SGT-212 uses a unique dual-route administration – a precise, MRI-guided infusion to the brain followed by an intravenous infusion – designed to target the neurologic, cardiac and systemic manifestations of FA by restoring functional frataxin levels. It’s a great conversation about the science, the clinical trial and our relentless focus on bringing meaningful therapies to patients who need them most. Check out the full interview here: checkrare.com/first-patient-… #FriedreichsAtaxia #RareDisease #GeneTherapy #PatientAdvocacy #ClinicalTrials

Solid Biosciences’ Medical Director and Therapeutic Head, Neuromuscular, Matthew Harmelink, MD, will be speaking at the Friedreich’s Ataxia Research Reception in Houston, TX. We’re excited to join @CureFA_org (FARA) to discuss Solid's FALCON gene therapy (SGT-212) Phase 1b study with the FA community.

Solid President and CEO Bo Cumbo and Gabriel Brooks, Chief Medical Officer, will be participating in a fireside chat at Barclays 28th Annual Global Healthcare Conference on Thursday, March 12, 2026, 11:30 a.m. ET. Catch the webcast at investors.solidbio.com/news-and-event…. $SLDB

Today, we shared an important update with the Duchenne community about the Phase 1/2 INSPIRE DUCHENNE clinical trial evaluating our investigational SGT-003 gene therapy program. Our interim clinical data were presented at the 2026 @MDAorg (MDA) Clinical & Scientific Conference earlier today. None of this progress would be possible without the brave study participants, their families, and our clinical site partners. We are deeply grateful for your continued partnership. To read the full community letter and learn more about the trial, visit: solidbio.com/letter-to-the-… #DuchenneAwareness #RareDiseaseResearch #DuchenneCommunity

At today’s #MDAConference, Solid delivered a positive interim clinical data update from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, our investigational gene therapy for the treatment of Duchenne muscular dystrophy. To learn more, visit investors.solidbio.com/news-releases/… #DuchenneMuscularDystrophy #Neuromuscular #GeneTherapy $SLDB @MDAorg

Solid Biosciences is pleased to announce an oral presentation at the 2026 @MDAorg (MDA) Clinical & Scientific Conference on Wednesday, March 11, at 1 p.m. ET. The presentation will feature a clinical data update from the INSPIRE DUCHENNE Phase 1/2 study of SGT-003, our next-generation Duchenne muscular dystrophy program. We will also exhibit five posters highlighting SGT-003’s benefits and differentiation as well as highlight SGT-212, our gene therapy candidate for the treatment of Friedreich’s ataxia. Read more here: investors.solidbio.com/news-releases/… #MDAConference $SLDB

Join us as we celebrate #RareDiseaseDay, a day dedicated to raising awareness and driving change for more than 30 million Americans affected by rare disease, including an estimated 15 million children. Today, we’re reminded of the importance of #RareDiseaseResearch. Solid strives to uplift scientific advancements to create hope for individuals and families living with rare diseases. We hope you’ll join us in spreading awareness and being an advocate for this special community. @RareDiseases @rarediseaseday #RDD2026

Solid is proud to sponsor @Parent_Project’s XXIII International Conference on Duchenne and Becker Muscular Dystrophy, taking place Feb. 27 - Mar. 1, in Rome. Annie Ganot, Head of Patient Advocacy and Co-Founder, Patrick Gonzalez, PhD, Head of Clinical Science, and Seth Rotberg, MNM, Senior Manager of Patient Advocacy, will be attending and on hand to engage with the community. Join us in Rome to advance progress for the #Duchenne and #Becker communities: parentproject.it/cosa-facciamo/…

Solid is proud to sponsor @JettFoundation’s #RareDiseaseDay event, ‘Advocating for Care Needs in Duchenne & Beyond’, taking place tomorrow, February 19 at 5:30 PM ET. This virtual panel will feature community members living with #Duchenne and other neuromuscular disorders sharing lived experiences and practical insights on self-advocacy across the rare disease journey. The discussion will be moderated by @SeanBaumstark and @KyleABryant, hosts of the @2DDPodcast. Learn more and register by visiting: jettfoundation.org/rare-disease-d…

Solid Biosciences today announced a positive regulatory update from our recent Type C meeting with the U.S. Food and Drug Administration (FDA): we have reached alignment with the FDA on the overall study design for our randomized, double-blind, placebo-controlled Phase 3 clinical trial, IMPACT DUCHENNE. Read the full release: investors.solidbio.com/news-releases/… $SLDB

Solid is pleased to share that our President and CEO, Bo Cumbo, will present at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, at 10:30 AM ET. A live webcast of the presentation can be accessed by visiting: investors.solidbio.com/news-releases/… $SLDB

Solid is proud to sponsor @DuchenneUK New Horizons 2026, taking place February 6-7 in London. Annie Ganot, SVP, Patient Advocacy, will join leaders from across the Duchenne community on the Industry Panel. We look forward to continuing important conversations in support of patients and families living with #Duchenne. Learn more: duchenneuk.org/new-horizons-c… #DuchenneUK #DuchenneMuscularDystrophy

In recognition of #AmericanHeartMonth, we’re reflecting on the voices that guide our work in rare cardiac disease. We were honored to welcome CPVT patient advocate, Jadale Mitchell, to the Solid office. Jadale shared his lived experience with #CPVT and his advocacy efforts to support patients and families through organizations like The @SADSFoundation. As we look to the year ahead, we remain focused on continuing our work in the cardiac and CPVT space, guided by patient voices and lived experience. To learn more about Jadale’s full story, visit our website: solidbio.com/patient-storie…

President and CEO Bo Cumbo will provide a corporate update outlining progress in advancing our neuromuscular and cardiac gene therapy programs at the 44th Annual @JPMorgan Healthcare Conference on Tuesday, January 13, at 5:15 PM PT / 8:15 PM ET. Learn more about our pipeline and platform technologies, and access a live webcast of the presentation by reading the full release: investors.solidbio.com/news-releases/… #JPM2026 #JPMHealthcare $SLDB

Yesterday, Solid Biosciences shared an important update with the Friedreich’s ataxia community. The first participant has been dosed in the Phase 1b FALCON trial evaluating SGT-212, our novel, investigational dual-route administration gene therapy for the treatment of FA. We are deeply grateful to the FA community, @CureFA_org, our clinical partners, and the patients and families whose trust and participation make this work possible. Your partnership continues to guide our mission to advance meaningful therapies for people living with FA. Read the full community letter here: solidbio.com/letter-to-the-… #FriedreichsAtaxia #FACommunity #RareDiseaseResearch

Solid Biosciences is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to SGT-212 for the treatment of Friedreich’s ataxia (FA). Read the full release: investors.solidbio.com/news-releases/… #FriedreichsAtaxia #GeneTherapy #RareDisease

Solid Biosciences today announced that the first participant has been dosed in FALCON, our Phase 1b, first-in-human clinical trial evaluating SGT-212. SGT-212 is our first-in-class investigational gene therapy for the treatment of Friedreich’s ataxia (FA) that employs a novel, dual-route administration designed to target the neurologic, cardiac and systemic manifestations of the disease. Learn more: investors.solidbio.com/news-releases/… #FriedreichsAtaxia #GeneTherapy #RareDisease

Solid Biosciences’ President and CEO, Bo Cumbo, will present at the 44th Annual @JPMorgan Healthcare Conference on Tuesday, January 13, at 5:15 PM PT (8:15 PM ET). Access the live presentation webcast here: investors.solidbio.com/news-releases/… #SolidBiosciences #JPM2026 #JPMorganHealthcare